Highlights

  • Yarrow closed an underwritten public offering worth USD 172.5 mn in gross proceeds during September 2026.
  • The company is studying YB-101 in a Phase 2a/2b trial for Graves’ disease, with or without thyroid eye disease.
  • Yarrow previously disclosed that Phase 2a top-line data were expected during the second half of 2027.
  • The company continues developing an anti-TSHR antibody designed to target the central disease mechanism.

Yarrow Bioscience (NASDAQ:YARW) is drawing fresh attention after its latest developments put yarrow yb-101 thyroid clinical programme and offering at the centre of its Investment narrative. The company’s disclosed milestones offer a clearer look at operating priorities, financial resources and what remains to be completed. Against that backdrop, shares gained 16.60% to USD 18.05 in the November 11, 2026 market figures. The distinction between progress already reported and milestones still planned remains essential when evaluating its next phase.

New Capital Supports Clinical Research

Yarrow Bioscience closed a USD 172.5 mn underwritten public offering in September 2026, including full exercise of the underwriters’ option to acquire additional shares.

The financing followed a September 10 pricing announcement for an initial USD 150 mn offering, before the additional option. The final gross amount reflects the completed offering rather than the original launch size.

YB-101 Targets Autoimmune Thyroid Disease

The clinical-stage company is developing YB-101, a monoclonal antibody directed at the thyroid-stimulating hormone receptor, known as TSHR. The candidate is intended to interrupt the central mechanism associated with Graves’ disease and thyroid eye disease.

Yarrow is studying YB-101 in a Phase 2a/2b trial enrolling patients with Graves’ disease, with or without thyroid eye disease. Dosing commenced following the company’s July update.

Trial Timeline Sets the Milestone

Yarrow previously indicated that Phase 2a top-line results were expected in the second half of 2027. The forecast is a company target, not a reported clinical outcome.

The company has also stated that it intends to use offering proceeds for pipeline Research and Development and general corporate purposes, including Working Capital and potential capital expenditure.

A Focused Clinical Strategy

Yarrow’s disclosed development strategy is centred on YB-101 and the possibility of addressing thyroidal and extra-thyroidal manifestations of autoimmune thyroid disease.

The funding announcement and ongoing trial establish two distinct areas of attention: resources available for research and the clinical evidence still to be generated. The programme remains investigational.

What Comes Next

For Yarrow Bioscience, the near-term focus remains the milestones outlined in its latest announcements rather than an assumed outcome. The developments described above combine confirmed activity with expectations that remain subject to company execution, regulatory processes where applicable, and later reporting. Those distinctions will matter as subsequent updates provide more information about timing and progress.

Yarrow Bioscience shares traded at USD 18.05, up 16.60%, in the November 11, 2026 market figures.